$13.785
-0.203 (-1.47%)收盘时
PMN 同业对比
In the context of the broader market, PMN competes directly with industry leaders such as NTHI and MXCT. With a market capitalization of $123.62M, it holds a significant position in the sector. When comparing efficiency, PMN's gross margin of N/A stands against NTHI's N/A and MXCT's 63.86%. Such benchmarking helps identify whether ProMIS Neurosciences Inc is trading at a premium or discount relative to its financial performance.
ProMIS Neurosciences Inc 财务表现
PMN has shown a significant increase in cash reserves, ending Q2 2026 with approximately $53.4 million, which supports ongoing operations and clinical trials. However, the company has faced substantial losses, with a net income loss of $11,729,656 in Q2 2026.
Financials
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。